Agios Pharmaceuticals (AGIO) Expected to Announce Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is projected to announce its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($1.96) per share and revenue of $12.0590 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $26.94 on Tuesday. The company has a 50-day simple moving average of $27.37 and a 200-day simple moving average of $34.31. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The firm has a market capitalization of $1.57 billion, a P/E ratio of -3.85 and a beta of 0.91.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 2,932 shares of the stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the sale, the insider owned 64,795 shares in the company, valued at $1,755,296.55. This trade represents a 4.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Brian Goff sold 18,703 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $506,664.27. Following the transaction, the chief executive officer directly owned 136,583 shares of the company’s stock, valued at $3,700,033.47. This represents a 12.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 33,503 shares of company stock valued at $910,745. 4.93% of the stock is owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AGIO. Voleon Capital Management LP bought a new stake in shares of Agios Pharmaceuticals during the third quarter worth $268,000. Cinctive Capital Management LP acquired a new position in Agios Pharmaceuticals during the 3rd quarter worth about $405,000. Two Sigma Securities LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth about $288,000. BNP Paribas Financial Markets increased its position in Agios Pharmaceuticals by 174.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 11,908 shares of the biopharmaceutical company’s stock valued at $396,000 after acquiring an additional 7,572 shares in the last quarter. Finally, Cerity Partners LLC bought a new position in shares of Agios Pharmaceuticals in the second quarter worth about $226,000.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Royal Bank Of Canada cut Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $57.00 to $28.00 in a report on Wednesday, November 19th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, December 29th. Leerink Partners upped their target price on Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, December 26th. Citigroup reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Friday, December 26th. Finally, Truist Financial boosted their price target on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $39.44.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.